Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
1999 1
2002 7
2003 6
2004 5
2005 10
2006 13
2007 16
2008 11
2009 15
2010 16
2011 18
2012 21
2013 28
2014 25
2015 31
2016 40
2017 30
2018 38
2019 41
2020 54
2021 65
2022 72
2023 52
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

574 results

Results by year

Filters applied: . Clear all
Page 1
CRISPR-Cas-mediated diagnostics.
Li L, Shen G, Wu M, Jiang J, Xia Q, Lin P. Li L, et al. Among authors: lin p. Trends Biotechnol. 2022 Nov;40(11):1326-1345. doi: 10.1016/j.tibtech.2022.04.006. Epub 2022 May 17. Trends Biotechnol. 2022. PMID: 35595574 Review.
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. Pfeffer MA, et al. Among authors: ping l. N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225. N Engl J Med. 2015. PMID: 26630143 Free article. Clinical Trial.
Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W, Dong X, Li Q, Cheng Z, Yuan G, Liu M, Xiao J, Gu S, Niemoeller E, Chen L, Ping L, Souhami E; LixiLan-O-AP trial investigators. Yang W, et al. Among authors: ping l. Diabetes Obes Metab. 2022 Aug;24(8):1522-1533. doi: 10.1111/dom.14722. Epub 2022 May 12. Diabetes Obes Metab. 2022. PMID: 35441412 Clinical Trial.
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM. Armstrong AJ, et al. Among authors: lin p. Eur Urol. 2020 Sep;78(3):347-357. doi: 10.1016/j.eururo.2020.04.061. Epub 2020 Jun 9. Eur Urol. 2020. PMID: 32527692 Free article. Clinical Trial.
Macrophage Plasticity and Atherosclerosis Therapy.
Lin P, Ji HH, Li YJ, Guo SD. Lin P, et al. Front Mol Biosci. 2021 May 7;8:679797. doi: 10.3389/fmolb.2021.679797. eCollection 2021. Front Mol Biosci. 2021. PMID: 34026849 Free PMC article. Review.
574 results